REGULATORY

• Japan Panel Backs Daiichi’s MMR Vaccine, Haihe’s PI3Kα Inhibitor, MSD’s HIV Med
  March 3, 2026

• MHLW Revises Guidance on Pediatric Development Plans under Amended PMD Act
  March 3, 2026

• MHLW Details New Operational Rules for Conditional Approvals from May
  March 3, 2026

• MHLW Seeks Sponsors to Develop 8 “Drug-Loss” Products
  March 2, 2026

• WG Members Urge Domestic Biologic Production as National Growth Strategy
  March 2, 2026

• MHLW Clarifies Up to 12-Year Data Protection for Pediatric Development
  March 2, 2026

• MHLW Issues 15 Notices Ahead of PMD Act Amendment
  March 2, 2026

• Celltrion’s Eylea Biosimilar Nears Approval, but Listing Outlook Clouded
  February 27, 2026

• Japan Panel to Review Joenja, Dojolvi for Approval at March 5 Session
  February 27, 2026

• Executives Urge Stronger CDMO, CRO Base at Drug Discovery WG Meeting
  February 27, 2026

• Japan to Closely Monitor US “MFN” Policy: PM Takaichi
  February 27, 2026

• Japan to Update Adult Pneumococcal Fact Sheet Ahead of Capvaxive NIP Review
  February 27, 2026

• Takaichi Signals Continued Off-Year Revisions despite Abolition Calls
  February 26, 2026

• LDP Panel Delays Approval of Health Insurance Bill amid Concerns over OTC-Like Drug Charges
  February 26, 2026

• MHLW Orders Colchicine Label Revision, Warns against Doses above 1.5 mg per Day
  February 26, 2026

• Symbicort Switch to OTC Status Gains No Support at MHLW Panel
  February 25, 2026

• Japan Govt Council Finalizes Recommendations for National MCM Strategy
  February 25, 2026

• Japan Panel to Review Haihe’s PI3Kα Inhibitor, MSD’s HIV Med, and More on March 2
  February 24, 2026

• PM Vows Comprehensive Support for 17 Priority Sectors: Policy Speech
  February 24, 2026

• Multiple Drug-Drug Interaction Risks under PMDA Review
  February 24, 2026

ページ

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »